Biogen Idec Issues Statement



    CAMBRIDGE, MASS., October 12 /CNW/ - Biogen Idec Inc. (NASDAQ:   BIIB)
today announced that its Board of Directors has authorized management to
evaluate whether third parties would have an interest in acquiring the Company
at a price and on terms that would represent a better value for its
stockholders than having the Company continue to execute its strategy on a
stand-alone basis.

    The Board emphasized that Biogen Idec's strategy is working and
generating strong operating and financial performance. The Board noted that it
is confident that the Company's business outlook, described in Biogen Idec's
press release on September 6, will result in attractive value for
stockholders. Nevertheless, to determine whether potential strategic interest
on the part of major pharmaceutical companies might result in superior value
in the current environment, the Board has authorized management to explore
interest in a transaction with Biogen Idec.

    In addition, the Company disclosed it has received expressions of
interest, including one from investor Carl Icahn. The Company does not intend
to disclose further information regarding the status of its evaluation until
the process has been completed. Biogen Idec emphasizes that there can be no
assurance that an acquisition of the Company will occur.

    To assist in this process, the Company has retained the services of
Goldman Sachs & Co. and Merrill Lynch & Co. as financial advisors.

    In a press release and in a presentation to investors on September 6,
2007, Biogen Idec announced a series of goals that it would seek to achieve by
year-end 2010. These include:

    --  100,000 patients on TYSABRI(R);

    --  More than 40% of the Company's revenue coming from its International
business;

    --  Four new products and/or existing products launched in new
indications;

    --  Six programs in late-stage clinical development; and

    --  Generating revenue growth at a 15% compound annual growth rate (CAGR)
and non-GAAP EPS at a 20% CAGR from 2007 through 2010.

    About Biogen Idec

    Biogen Idec creates new standards of care in therapeutic areas with high
unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the
discovery, development, manufacturing, and commercialization of innovative
therapies. Patients in more than 90 countries benefit from Biogen Idec's
significant products that address diseases such as lymphoma, multiple
sclerosis, and rheumatoid arthritis. For product labeling, press releases and
additional information about the company, please visit www.biogenidec.com.

    Safe Harbor

    This press release contains forward-looking statements about our expected
revenues, earnings, cash flows, product sales, product development and other
matters. Forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially from that which we
expect. Important factors that could cause our actual results to differ
include our continued dependence on our two principal products, AVONEX(R) and
RITUXAN(R), the uncertainty of success in commercializing other products
including TYSABRI(R), the occurrence of adverse safety events with our
products, the failure to execute our growth strategy successfully or to
compete effectively in our markets, our dependence on collaborations over
which we may not always have full control, possible adverse impact of
government regulation and changes in the availability of reimbursement for our
products, problems with our manufacturing processes and our reliance on third
parties, fluctuations in our operating results, our ability to protect our
intellectual property rights and the cost of doing so, the risks of doing
business internationally and the other risks and uncertainties that are
described in Item 1A "Risk Factors" in our most recent Form 10-Q filing with
the SEC. These forward-looking statements speak only as of the date of this
press release, and we do not undertake any obligation to publicly update any
forward-looking statements, whether as a result of new information, future
events, or otherwise.




For further information:

For further information: MEDIA CONTACT: Biogen Idec Naomi Aoki,
617-914-6524 or INVESTOR COMMUNITY CONTACT: Biogen Idec Elizabeth Woo,
617-679-2812

Organization Profile

BIOGEN IDEC

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890